Publications
36
Citations
283
Est. group size
—
Recurring co-author estimate
Active years
33
Publishing since 1993
Sreenath Nair's work focuses on how chemotherapy drugs behave in the body (pharmacokinetics) and cause side effects (toxicity) in children being treated for cancers such as brain tumors and soft-tissue sarcomas. This includes developing lab methods to measure drug levels in blood plasma and studying biomarkers that could predict drug-induced organ damage, such as kidney toxicity from cisplatin. The research aims to improve dosing safety and effectiveness for pediatric cancer patients.
Publication output was low and sporadic for most of the past decade but spiked sharply in 2023, likely reflecting a single major study with extensive supplementary materials, before dropping back to a lower, steadier level in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Quantitative determination of Selinexor concentrations in plasma samples from children with non-rhabdomyosarcoma soft-tissue sarcomas: Troubleshooting plasma instability issues
Journal of Chromatography B · 2025
- Quantitative determination of liposomal irinotecan and SN-38 concentrations in plasma samples from children with solid tumors: Use of a cryoprotectant solution to enhance liposome stability
Journal of Chromatography B · 2024
- Identification of Novel and Early Biomarkers for Cisplatin-induced Nephrotoxicity and the Nephroprotective Role of Cimetidine using a Pharmacometabolomic-based Approach Coupled with In Vitro Toxicodynamic Modeling and Simulation
Journal of Pharmaceutical Sciences · 2023
- Figure S7 from Exposure–Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing
2023
- Supplementary Data from Exposure–Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing
2023
- Figure S6 from Exposure–Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing
2023
- Figure S3 from Exposure–Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing
2023
- Figure S2 from Exposure–Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing
2023
- Figure S5 from Exposure–Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing
2023
- Figure S1 from Exposure–Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing
2023
- Figure S4 from Exposure–Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing
2023
- Figure S4 from Exposure–Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing
2023
- Supplementary Data from Exposure–Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing
2023
- Figure S3 from Exposure–Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing
2023
- Figure S7 from Exposure–Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing
2023
- Nature Communications×2
- Journal of Chromatography B×2
- New England Journal of Medicine×1
- Clinical Cancer Research×1
- Molecules×1
- Julie M. Gastier‐Foster
Medicine · The Ohio State University
- Anna Eames Seffernick
Medicine · The Ohio State University
- A W Craft
Medicine · The Ohio State University
- Chunhua Song
Medicine · The Ohio State University
- Mahvish Q. Rahim
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile